Estimates Revisions Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
04:00:03 2026-09-01 pm EDT
|
5-day change | 1st Jan Change | ||
| 282.34 USD | -2.05% |
|
-5.44% | +41.54% |
| Aug. 20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| Aug. 20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- CRL Stock
- Consensus Charles River Laboratories International, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
